Retatrutide (development code LY3437943) is an investigational once-weekly injectable weight loss medication developed by Eli Lilly and Company the same pharmaceutical company behind Mounjaro (tirzepatide) and the oral GLP-1 pill orforglipron (Foundayo)
In 2026, we welcome William Meller, MD, to the helm
La simple medicin del peso no permite identificar estas modificaciones
Proteins were transferred to PVDF membranes (Immobilon-P, 0.45-m pore size, Sigma-Aldrich) using a wet transfer Western blot system (Bio-Rad) and membranes blocked in 5% BSA in 1x TBS/Tween (20 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20) before incubation with a mouse monoclonal anti-pan-phospho-serine primary antibody (M380B, Biolegend, 1:1,000) also in 5% BSA in 1x TBS/Tween followed by 3x washes in 1x TBS/Tween and incubation with goat anti-mouse HRP secondary antibody (ab205719, Abcam, 1:5,000) before being developed using the Clarity Western enhanced chemiluminescence substrate system (Bio-Rad) in a ChemiDoc imaging system (Bio-Rad)
Enhances Metabolism: NAD supports the bodys ability to burn fat and maintain a healthy metabolic rate
Receive full instructions, injection guidance, and lifestyle support
